Badiger; Sangamesh

Patent Applications and Registrations

Patent applications and USPTO patent grants for Badiger; Sangamesh.The latest application filed is for "novel heterocyclic derivatives and their use in the treatment of neurological disorders".

Company Profile

4.14.19

Badiger; Sangamesh - Bangalore IN
Badiger; Sangamesh - Karnataka N/A IN
Badiger; Sangamesh - Tamil Nadu IN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 10,683,287 - Badiger , et al.	2020-06-16
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20200048236 - Badiger; Sangamesh ; et al.	2020-02-13
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 10,301,296 - Badiger , et al.	2019-05-28
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20190062319 - Badiger; Sangamesh ; et al.	2019-02-28
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 10,035,794 - Badiger , et al. July 31, 2	2018-07-31
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20170320864 - BADIGER; Sangamesh ; et al.	2017-11-09
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 9,550,758 - Badiger , et al. January 24, 2	2017-01-24
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20150203481 - BADIGER; Sangamesh ; et al.	2015-07-23
Oxazine Derivatives And Their Use In The Treatment Of Neurological Disorders App 20150018338 - BADIGER; Sangamesh ; et al.	2015-01-15
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 8,865,712 - Badiger , et al. October 21, 2	2014-10-21
Disubstituted heteroaryl-fused pyridines Grant 8,742,106 - Badiger , et al. June 3, 2	2014-06-03
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20140107118 - BADIGER; Sangamesh ; et al.	2014-04-17
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 8,637,508 - Badiger , et al. January 28, 2	2014-01-28
Diaza-spiro[5.5]undecanes Useful As Orexin Receptor Antagonists App 20130281463 - Badiger; Sangamesh ; et al.	2013-10-24
Diaza-spiro[5.5]undecanes Grant 8,530,648 - Badiger , et al. September 10, 2	2013-09-10
Oxazine Derivatives And Their Use In The Treatment Of Neurological Disorders App 20120302558 - Badiger; Sangamesh ; et al.	2012-11-29
Diaza-spiro[5.5]undecanes App 20120264748 - Badiger; Sangamesh ; et al.	2012-10-18
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20120184539 - BADIGER; Sangamesh ; et al.	2012-07-19
Oxazine Derivatives and their Use in the Treatment of Neurological Disorders App 20120172359 - BADIGER; Sangamesh ; et al.	2012-07-05
Di/tri-aza-spiro-C9-C11alkanes App 20120165331 - BADIGER; Sangamesh ; et al.	2012-06-28
Diaza-spiro[5.5]undecanes App 20120101110 - BADIGER; Sangamesh ; et al.	2012-04-26
Oxazine Derivatives And Their Use In The Treatment Of Neurological Disorders App 20110021520 - BADIGER; Sangamesh ; et al.	2011-01-27
Diphenyl ether derivatives Grant 7,521,465 - Nag , et al. April 21, 2	2009-04-21
Novel diphenyl ether derivatives App 20050288341 - Nag, Bishwajit ; et al.	2005-12-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.